Viktor Mravčík1,2, Simona Kumpanová Valachovičová1, Jindřich Vobořil1. 1. Spolecnost Podane ruce, Brno, Czech Republic. 2. Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Abstract
OBJECTIVES: Understanding immune response is critical for control of COVID-19 pandemic. However, recent studies show that vaccine-induced humoral immunity may not be long-lasting and weaker in SARS-CoV-2 variants of concern. METHODS: In May 2021, 253 self-nominated persons were tested for antibodies against SARS-CoV-2 in 1 to 104 days (mean 41, median 28) after two doses of Moderna and Pfizer-BioNTech vaccines in the city of Brno, Czechia. Two point-of-care iCHROMA™ II immunofluorescence assays were used: COVID-19 Ab against mix of SARS-CoV-2 nucleocapsid and spike proteins (IgG Ab); and COVID-19 nAb against S1-RBD protein (nAb). Results were analysed in relation to gender, age, vaccine, and past COVID-19 disease. RESULTS: Antibodies nAb were detectable in 92.9% (95% CI: 89.7-96.0) of vaccinees. We observed statistically insignificant decrease of positive results from 93.9% (95% CI: 89.5-98.3) and 97.0% (95% CI: 92.8-100.0) in the first and second month after vaccination, respectively, to 91.7% (95% CI: 83.8-99.5) and 78.3% (95% CI: 61.4-95.1) in the third and fourth month, respectively. Quantitative results showed decreasing level of nAb in both genders, age groups and vaccines. Higher levels of nAb were found in younger age group and in COVID-19 convalescents. IgG Ab showed little dynamics in time. CONCLUSIONS: We found robust humoral response after vaccination with mRNA vaccines, however, decreasing nAb levels suggest that vaccine-induced humoral immunity is rapidly waning. This finding is relevant for adjustment of vaccination strategies with regard to inclusion of booster dose(s).
OBJECTIVES: Understanding immune response is critical for control of COVID-19 pandemic. However, recent studies show that vaccine-induced humoral immunity may not be long-lasting and weaker in SARS-CoV-2 variants of concern. METHODS: In May 2021, 253 self-nominated persons were tested for antibodies against SARS-CoV-2 in 1 to 104 days (mean 41, median 28) after two doses of Moderna and Pfizer-BioNTech vaccines in the city of Brno, Czechia. Two point-of-care iCHROMA™ II immunofluorescence assays were used: COVID-19 Ab against mix of SARS-CoV-2 nucleocapsid and spike proteins (IgG Ab); and COVID-19 nAb against S1-RBD protein (nAb). Results were analysed in relation to gender, age, vaccine, and past COVID-19 disease. RESULTS: Antibodies nAb were detectable in 92.9% (95% CI: 89.7-96.0) of vaccinees. We observed statistically insignificant decrease of positive results from 93.9% (95% CI: 89.5-98.3) and 97.0% (95% CI: 92.8-100.0) in the first and second month after vaccination, respectively, to 91.7% (95% CI: 83.8-99.5) and 78.3% (95% CI: 61.4-95.1) in the third and fourth month, respectively. Quantitative results showed decreasing level of nAb in both genders, age groups and vaccines. Higher levels of nAb were found in younger age group and in COVID-19 convalescents. IgG Ab showed little dynamics in time. CONCLUSIONS: We found robust humoral response after vaccination with mRNA vaccines, however, decreasing nAb levels suggest that vaccine-induced humoral immunity is rapidly waning. This finding is relevant for adjustment of vaccination strategies with regard to inclusion of booster dose(s).
Authors: Piyada Supasa; Daming Zhou; Wanwisa Dejnirattisai; Chang Liu; Alexander J Mentzer; Helen M Ginn; Yuguang Zhao; Helen M E Duyvesteyn; Rungtiwa Nutalai; Aekkachai Tuekprakhon; Beibei Wang; Guido C Paesen; Jose Slon-Campos; César López-Camacho; Bassam Hallis; Naomi Coombes; Kevin R Bewley; Sue Charlton; Thomas S Walter; Eleanor Barnes; Susanna J Dunachie; Donal Skelly; Sheila F Lumley; Natalie Baker; Imam Shaik; Holly E Humphries; Kerry Godwin; Nick Gent; Alex Sienkiewicz; Christina Dold; Robert Levin; Tao Dong; Andrew J Pollard; Julian C Knight; Paul Klenerman; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah Gilbert; David R Hall; Mark A Williams; Neil G Paterson; William James; Miles W Carroll; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton Journal: Cell Date: 2021-02-18 Impact factor: 41.582
Authors: Rishi R Goel; Sokratis A Apostolidis; Mark M Painter; Divij Mathew; Ajinkya Pattekar; Oliva Kuthuru; Sigrid Gouma; Leticia Kuri-Cervantes; Wenzhao Meng; Sharon Adamski; Amy E Baxter; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Amanda Hicks; Scott Korte; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Eline T Luning Prak; Michael R Betts; Paul Bates; Scott E Hensley; Allison R Greenplate; E John Wherry Journal: medRxiv Date: 2021-03-06
Authors: Jennifer M Dan; Jose Mateus; Yu Kato; Kathryn M Hastie; Esther Dawen Yu; Caterina E Faliti; Alba Grifoni; Sydney I Ramirez; Sonya Haupt; April Frazier; Catherine Nakao; Vamseedhar Rayaprolu; Stephen A Rawlings; Bjoern Peters; Florian Krammer; Viviana Simon; Erica Ollmann Saphire; Davey M Smith; Daniela Weiskopf; Alessandro Sette; Shane Crotty Journal: Science Date: 2021-01-06 Impact factor: 47.728
Authors: Sandile Cele; Laurelle Jackson; David S Khoury; Khadija Khan; Thandeka Moyo-Gwete; Houriiyah Tegally; James Emmanuel San; Deborah Cromer; Cathrine Scheepers; Daniel Amoako; Farina Karim; Mallory Bernstein; Gila Lustig; Derseree Archary; Muneerah Smith; Yashica Ganga; Zesuliwe Jule; Kajal Reedoy; Shi-Hsia Hwa; Jennifer Giandhari; Jonathan M Blackburn; Bernadett I Gosnell; Salim S Abdool Karim; Willem Hanekom; Anne von Gottberg; Jinal Bhiman; Richard J Lessells; Mahomed-Yunus S Moosa; Miles P Davenport; Tulio de Oliveira; Penny L Moore; Alex Sigal Journal: medRxiv Date: 2021-12-17
Authors: Yunkai Yu; Dominic Esposito; Zhigang Kang; Jianming Lu; Alan T Remaley; Valeria De Giorgi; Leonard N Chen; Kamille West; Liang Cao Journal: Sci Rep Date: 2022-02-16 Impact factor: 4.996
Authors: Jeffrey Seow; Carl Graham; Blair Merrick; Sam Acors; Suzanne Pickering; Kathryn J A Steel; Oliver Hemmings; Aoife O'Byrne; Neophytos Kouphou; Rui Pedro Galao; Gilberto Betancor; Harry D Wilson; Adrian W Signell; Helena Winstone; Claire Kerridge; Isabella Huettner; Jose M Jimenez-Guardeño; Maria Jose Lista; Nigel Temperton; Luke B Snell; Karen Bisnauthsing; Amelia Moore; Adrian Green; Lauren Martinez; Brielle Stokes; Johanna Honey; Alba Izquierdo-Barras; Gill Arbane; Amita Patel; Mark Kia Ik Tan; Lorcan O'Connell; Geraldine O'Hara; Eithne MacMahon; Sam Douthwaite; Gaia Nebbia; Rahul Batra; Rocio Martinez-Nunez; Manu Shankar-Hari; Jonathan D Edgeworth; Stuart J D Neil; Michael H Malim; Katie J Doores Journal: Nat Microbiol Date: 2020-10-26 Impact factor: 17.745
Authors: Chang Liu; Helen M Ginn; Wanwisa Dejnirattisai; Piyada Supasa; Beibei Wang; Aekkachai Tuekprakhon; Rungtiwa Nutalai; Daming Zhou; Alexander J Mentzer; Yuguang Zhao; Helen M E Duyvesteyn; César López-Camacho; Jose Slon-Campos; Thomas S Walter; Donal Skelly; Sile Ann Johnson; Thomas G Ritter; Chris Mason; Sue Ann Costa Clemens; Felipe Gomes Naveca; Valdinete Nascimento; Fernanda Nascimento; Cristiano Fernandes da Costa; Paola Cristina Resende; Alex Pauvolid-Correa; Marilda M Siqueira; Christina Dold; Nigel Temperton; Tao Dong; Andrew J Pollard; Julian C Knight; Derrick Crook; Teresa Lambe; Elizabeth Clutterbuck; Sagida Bibi; Amy Flaxman; Mustapha Bittaye; Sandra Belij-Rammerstorfer; Sarah C Gilbert; Tariq Malik; Miles W Carroll; Paul Klenerman; Eleanor Barnes; Susanna J Dunachie; Vicky Baillie; Natali Serafin; Zanele Ditse; Kelly Da Silva; Neil G Paterson; Mark A Williams; David R Hall; Shabir Madhi; Marta C Nunes; Philip Goulder; Elizabeth E Fry; Juthathip Mongkolsapaya; Jingshan Ren; David I Stuart; Gavin R Screaton Journal: Cell Date: 2021-06-17 Impact factor: 41.582